The impact of medetomidine on the protein‐binding characteristics ofMK‐467 in canine plasma
- 14 January 2016
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 39 (4) , 405-407
Abstract
This study determined the unbound fraction of the peripheralα2‐adrenoceptor antagonistMK‐467 alone and combined with medetomidine.MK‐467 (0.1, 1 and 10 μm) was incubated in canine plasma with and without medetomidine (molar ratio 20:1), with human serum albumin (HSA) and withα1‐acid glycoprotein (AGP). Rapid equilibrium dialysis was used for the measurement of protein binding. All samples were analysed by liquid chromatography and tandem mass spectrometry to obtain the unbound fraction (fu) ofMK‐467. Unbound fractions (fu) ofMK‐467 in canine plasma (mean ± standard deviation) were 27.6 ± 3.5%, 26.6 ± 0.9% and 42.4 ± 1.2% at 0.1, 1.0 and 10 μmconcentrations, respectively. In the presence of medetomidine,fuwere 27.5 ± 0.4%, 26.6 ± 0.9% and 41.0 ± 2.4%. ThefuofMK‐467 inHSAwere 50.1 ± 2.5% at 0.1 μm, 49.4 ± 1.2% at 1.0 μmand 56.7 ± 0.5% at 10 μm.fuofMK‐467 inAGPwas 56.3 ± 3.7% at 0.1 μm, 54.6 ± 5.6% at 1.0 μmand 65.3 ± 0.4% at 10 μm. Protein binding ofMK‐467 was approximately 70% between 0.1 and 1.0 μm. Medetomidine had no apparent effect on the protein binding ofMK‐467.Keywords
Funding Information
- Vetcare Ltd
- ANIWEL graduate school, University of Helsinki, Finland
This publication has 14 references indexed in Scilit:
- Haemodynamic interactions of medetomidine and the peripheral alpha-2 antagonist MK-467 during step infusions in isoflurane-anaesthetised dogsThe Veterinary Journal, 2014
- A comparison in dogs of medetomidine, with or without MK-467, and the combination acepromazine-butorphanol as premedication prior to anaesthesia induced by propofol and maintained with isofluraneVeterinary Anaesthesia and Analgesia, 2014
- Plasma glucose, insulin, free fatty acids, lactate and cortisol concentrations in dexmedetomidine-sedated dogs with or without MK-467: A peripheral α-2 adrenoceptor antagonistThe Veterinary Journal, 2012
- Cardiopulmonary and sedative effects of the peripheral α2-adrenoceptor antagonist MK 0467 administered intravenously or intramuscularly concurrently with medetomidine in dogsAmerican Journal of Veterinary Research, 2012
- Influence of MK-467, a Peripherally Acting α2-Adrenoceptor Antagonist on the Disposition of Intravenous Dexmedetomidine in DogsDrug Metabolism and Disposition, 2012
- The effects of increasing doses of MK‐467, a peripheral alpha2‐adrenergic receptor antagonist, on the cardiopulmonary effects of intravenous dexmedetomidine in conscious dogsJournal of Veterinary Pharmacology and Therapeutics, 2010
- The effects of L-659,066, a peripheral α2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia in dogsVeterinary Anaesthesia and Analgesia, 2008
- Effects of a peripheral α2 adrenergic-receptor antagonist on the hemodynamic changes induced by medetomidine administration in conscious dogsAmerican Journal of Veterinary Research, 2008
- Changes in plasma protein binding have little clinical relevanceClinical Pharmacology & Therapeutics, 2002
- Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogsJournal of Veterinary Pharmacology and Therapeutics, 2000